

AMENDMENT

Kindly amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

IN THE CLAIMS:

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents to read as follows:

1. (Previously Amended) A composition for therapy for reducing or treating restenosis and/or atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation.

3. (Previously Amended) The composition of claim 1 wherein the protein agent for inhibiting VEGF is a soluble VEGF receptor.

4. (Previously Amended) The composition of claim 1 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

5. (Twice Amended) The composition of claim 3 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

8. (Amended) A method for reducing or treating atherosclerosis or restenosis comprising administering a composition as claimed in claim 1.

9. (Twice Amended) A kit for formulating a composition for reducing or treating restenosis and/or atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in the same container.

10. (Twice Amended) A kit for formulating a composition for reducing or treating restenosis and/or atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in separate containers.

11. (Original) The kit of claim 10 wherein separate containers are in a package together.

---

18. (New) A composition for therapy for reducing or treating restenosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation.

19. (New) The composition of claim 18 wherein the protein agent for inhibiting VEGF is a soluble VEGF receptor.

20. (New) The composition of claim 18 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

21. (New) The composition of claim 19 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

22. (New) A method for reducing or treating restenosis comprising administering a composition as claimed in claim 18.

23. (New) A kit for formulating the composition of claim 18 for reducing or treating restenosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in the same container.

24. (New) A kit for formulating the composition of claim 18 for reducing or treating restenosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in separate containers.

25. (New) The kit of claim 24 wherein separate containers are in a package together.

26. (New) A composition for therapy for reducing or treating atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation.

27. (New) The composition of claim 26 wherein the protein agent for inhibiting VEGF is a soluble VEGF receptor.

28. (New) The composition of claim 26 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

29. (New) The composition of claim 27 wherein the protein agent for inducing vessel maturation comprises angiopoietin-1.

30. (New) A method for reducing or treating atherosclerosis comprising administering a composition as claimed in claim 26.

31. (New) A kit for formulating the composition of claim 26 for reducing or treating atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in the same container.

32. (New) A kit for formulating the composition of claim 26 for reducing or treating atherosclerosis comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in separate containers.

33. (New) The kit of claim 32 wherein separate containers are in a package together.